Novavax NVAX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's business segments — R&D?
- Novavax (NVAX) reported business segments — R&D of $38.06M in Q1 2026.
- How has Novavax's business segments — R&D changed year-over-year?
- Novavax's business segments — R&D decreased by 4.6% year-over-year, from $39.91M to $38.06M.
- What is the long-term trend for Novavax's business segments — R&D?
- Over 3 years (2022 to 2025), Novavax's business segments — R&D has grown at a -43.9% compound annual growth rate (CAGR), from $848.04M to $149.38M.
- What does business segments — R&D mean?
- Captures the expenses incurred by the reportable segment for the discovery, development, and clinical testing of new products or technologies. This investment is critical for long-term innovation and future revenue potential, particularly in biotechnology sectors where product pipelines drive market value.